解读非住院溃疡性结肠炎患者内科治疗临床实践指南——多伦多共识  

Clinical practice guidelines for the medical management of non-hospitalized ulcerative colitis: the Toronto consensus

作　　者：江学良[1] 

机构地区：[1]济南军区总医院消化科,250031

出　　处：《中华消化病与影像杂志（电子版）》2016年第2期49-52,共4页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

摘　　要：2015年非住院溃疡性结肠炎患者内科治疗临床实践指南―多伦多共识主要包括5个方面要点:(1)5-氨基水杨酸类药物仍然是治疗轻中度溃疡性结肠炎的一线药物;(2)糖皮质激素只用于活动性溃疡性结肠炎的诱导缓解,不用于维持治疗;(3)免疫制剂不能用于诱导缓解,可以用于维持缓解,其作用和地位有所下降;(4)生物制剂已经成为中重度或者顽固性溃疡性结肠炎一线或者二线治疗药物;(5)粪微生物移植等探索性临床研究仍缺乏大规模多中心临床验证。本文对有关内容进行介绍并加以解读。Clinical practice guidelines for the medical management of non-hospitalized ulcerative colitis（ UC）（ the Toronto consensus） include： Oral and rectal 5-aminosalicylic acids（ 5-ASAs） are recommended first-line therapy for mild to moderate UC. Glucocorticoids are only used for remission induction of patients with active UC,and are not used for maintenance treatment. Immune stimulants can not be used for remission induction,and can be used for maintenance treatment. The functions and status of immune stimulants decrease to some extent. Biological agents are the first or second-line treatment drugs for patients with moderate to severe or refractory UC. Fecal microbial transplant is not recommended to induce or maintain complete remission outside the setting of a clinical trial. This review will introduce and interpret the related contents.

关 键 词：结肠炎 溃疡性 氨基水杨酸类 糖皮质激素类 硫唑嘌呤 抗肿瘤坏死因子单抗 粪微生物移植 

分 类 号：R574.62[医药卫生—消化系统]